FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056959009> ?p ?o ?g. }

• W2056959009 endingPage "60" @default.
• W2056959009 startingPage "57" @default.
• W2056959009 abstract "Thymic malignancies are rare, and options are limited for metastatic disease. Src plays a role in normal thymic epithelial maturation, and its inhibition with the oral compound saracatinib was postulated to be effective in controlling thymic malignancy.Patients with unresectable thymic malignancy were treated with saracatinib 175mg by mouth daily in 28 days cycles with radiographic evaluation at cycle 2 day 1 for safety, then cycle 3 day 1 and every 8 weeks thereafter. Response was evaluated by RECIST 1.0. A two-stage optimal design was used, powered to detect a true response rate of 20%.21 patients were enrolled at two institutions, 12 of them with thymoma, 9 with thymic carcinoma. Thymoma patients received a median of 4.5 cycles and thymic carcinoma patients a median of 1 cycle. There were no responses, so accrual was halted after the first stage per protocol. 9 patients had stable disease beyond the first assessment. Median time to progression was 5.7 months for thymoma patients and 3.6 months for thymic carcinoma patients. Saracatinib was well tolerated.Src inhibition by saracatinib did not produce any radiographic responses, though some patients did experience stable disease. Though negative, this study shows the feasibility of completing a trial in this rare disease, and of accruing reasonably significant numbers of thymic carcinoma patients. More clinical trials are required for this population (NCT00718809)." @default.
• W2056959009 created "2016-06-24" @default.
• W2056959009 creator A5011938575 @default.
• W2056959009 creator A5020424951 @default.
• W2056959009 creator A5021904320 @default.
• W2056959009 creator A5035640724 @default.
• W2056959009 creator A5054859053 @default.
• W2056959009 creator A5055548058 @default.
• W2056959009 creator A5085319465 @default.
• W2056959009 date "2015-07-01" @default.
• W2056959009 modified "2023-10-01" @default.
• W2056959009 title "A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies" @default.
• W2056959009 cites W1867931780 @default.
• W2056959009 cites W1881109350 @default.
• W2056959009 cites W1971882888 @default.
• W2056959009 cites W1975225467 @default.
• W2056959009 cites W1977455794 @default.
• W2056959009 cites W1990915902 @default.
• W2056959009 cites W1997214058 @default.
• W2056959009 cites W2053244130 @default.
• W2056959009 cites W2085485812 @default.
• W2056959009 cites W2108426094 @default.
• W2056959009 cites W2127283584 @default.
• W2056959009 cites W2128501533 @default.
• W2056959009 cites W2130099089 @default.
• W2056959009 cites W2133713996 @default.
• W2056959009 cites W2139863684 @default.
• W2056959009 cites W2160612042 @default.
• W2056959009 cites W2167601464 @default.
• W2056959009 cites W2168558240 @default.
• W2056959009 cites W4214561329 @default.
• W2056959009 doi "https://doi.org/10.1016/j.lungcan.2015.04.008" @default.
• W2056959009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26009269" @default.
• W2056959009 hasPublicationYear "2015" @default.
• W2056959009 type Work @default.
• W2056959009 sameAs 2056959009 @default.
• W2056959009 citedByCount "30" @default.
• W2056959009 countsByYear W20569590092014 @default.
• W2056959009 countsByYear W20569590092015 @default.
• W2056959009 countsByYear W20569590092016 @default.
• W2056959009 countsByYear W20569590092017 @default.
• W2056959009 countsByYear W20569590092018 @default.
• W2056959009 countsByYear W20569590092019 @default.
• W2056959009 countsByYear W20569590092020 @default.
• W2056959009 countsByYear W20569590092021 @default.
• W2056959009 countsByYear W20569590092022 @default.
• W2056959009 countsByYear W20569590092023 @default.
• W2056959009 crossrefType "journal-article" @default.
• W2056959009 hasAuthorship W2056959009A5011938575 @default.
• W2056959009 hasAuthorship W2056959009A5020424951 @default.
• W2056959009 hasAuthorship W2056959009A5021904320 @default.
• W2056959009 hasAuthorship W2056959009A5035640724 @default.
• W2056959009 hasAuthorship W2056959009A5054859053 @default.
• W2056959009 hasAuthorship W2056959009A5055548058 @default.
• W2056959009 hasAuthorship W2056959009A5085319465 @default.
• W2056959009 hasConcept C126322002 @default.
• W2056959009 hasConcept C141071460 @default.
• W2056959009 hasConcept C143998085 @default.
• W2056959009 hasConcept C146357865 @default.
• W2056959009 hasConcept C151730666 @default.
• W2056959009 hasConcept C2776349617 @default.
• W2056959009 hasConcept C2777546739 @default.
• W2056959009 hasConcept C2779134260 @default.
• W2056959009 hasConcept C2779159893 @default.
• W2056959009 hasConcept C2779399171 @default.
• W2056959009 hasConcept C2908647359 @default.
• W2056959009 hasConcept C71924100 @default.
• W2056959009 hasConcept C86803240 @default.
• W2056959009 hasConcept C90924648 @default.
• W2056959009 hasConcept C99454951 @default.
• W2056959009 hasConceptScore W2056959009C126322002 @default.
• W2056959009 hasConceptScore W2056959009C141071460 @default.
• W2056959009 hasConceptScore W2056959009C143998085 @default.
• W2056959009 hasConceptScore W2056959009C146357865 @default.
• W2056959009 hasConceptScore W2056959009C151730666 @default.
• W2056959009 hasConceptScore W2056959009C2776349617 @default.
• W2056959009 hasConceptScore W2056959009C2777546739 @default.
• W2056959009 hasConceptScore W2056959009C2779134260 @default.
• W2056959009 hasConceptScore W2056959009C2779159893 @default.
• W2056959009 hasConceptScore W2056959009C2779399171 @default.
• W2056959009 hasConceptScore W2056959009C2908647359 @default.
• W2056959009 hasConceptScore W2056959009C71924100 @default.
• W2056959009 hasConceptScore W2056959009C86803240 @default.
• W2056959009 hasConceptScore W2056959009C90924648 @default.
• W2056959009 hasConceptScore W2056959009C99454951 @default.
• W2056959009 hasFunder F4320307770 @default.
• W2056959009 hasIssue "1" @default.
• W2056959009 hasLocation W20569590091 @default.
• W2056959009 hasLocation W20569590092 @default.
• W2056959009 hasOpenAccess W2056959009 @default.
• W2056959009 hasPrimaryLocation W20569590091 @default.
• W2056959009 hasRelatedWork W1993423771 @default.
• W2056959009 hasRelatedWork W2143634093 @default.
• W2056959009 hasRelatedWork W2154511406 @default.
• W2056959009 hasRelatedWork W2155799072 @default.
• W2056959009 hasRelatedWork W2271211741 @default.
• W2056959009 hasRelatedWork W2417805311 @default.
• W2056959009 hasRelatedWork W2573737664 @default.

• next